Biologically Active Small Molecules

A potent anti-tumor agent used as a selective and irreversible inhibitor of the 20S proteasome inhibits proteasome activity in cell growth assays (IC50 = 4 nM) and demonstrates potent cytotoxicity against B16-F10, HCT116, and Moser solid tumor

A potent anti-tumor agent used as a selective and irreversible inhibitor of the 20S proteasome inhibits proteasome activity in cell growth assays (IC50 = 4 nM) and demonstrates potent cytotoxicity against B16-F10, HCT116, and Moser solid tumor

A potent anti-tumor agent used as a selective and irreversible inhibitor of the 20S proteasome inhibits proteasome activity in cell growth assays (IC50 = 4 nM) and demonstrates potent cytotoxicity against B16-F10, HCT116, and Moser solid tumor

A potent anti-tumor agent used as a selective and irreversible inhibitor of the 20S proteasome inhibits proteasome activity in cell growth assays (IC50 = 4 nM) and demonstrates potent cytotoxicity against B16-F10, HCT116, and Moser solid tumor

A sensitive fluorescent substrate for sEH that can be used to monitor the activity of both human and mouse enzymes.

A sensitive fluorescent substrate for sEH that can be used to monitor the activity of both human and mouse enzymes.

A sensitive fluorescent substrate for sEH that can be used to monitor the activity of both human and mouse enzymes.

A sensitive fluorescent substrate for sEH that can be used to monitor the activity of both human and mouse enzymes.

A competitive AT1 receptor antagonist (IC50s 1.4 &ndash 3.9 nM and an elimination half-life of 5 to 7 hours) that blocks angiotensin II receptors on both sympathetic nerve terminals and blood vessels.

A competitive AT1 receptor antagonist (IC50s 1.4 &ndash 3.9 nM and an elimination half-life of 5 to 7 hours) that blocks angiotensin II receptors on both sympathetic nerve terminals and blood vessels.

A competitive AT1 receptor antagonist (IC50s 1.4 &ndash 3.9 nM and an elimination half-life of 5 to 7 hours) that blocks angiotensin II receptors on both sympathetic nerve terminals and blood vessels.

A potent DOT1L inhibitor (IC₅₀ = 400 pM) that selectively kills (MLL) cells in vitro and prolongs survival in an MLL xenograft mouse model accelerates the reprogramming of somatic cells into induced pluripotent stem cells.